Nasal mRNA Therapy Cuts Rhinovirus Load in Asthma
Ethris reported topline phase 2a results for its investigational ETH47 candidate in adults with symptomatic asthma challenged with rhinovirus.
Updated on Nov. 5, 2026 in Asthma
Ethris announced topline phase 2a data showing its investigational nasal messenger RNA therapy ETH47 reduced peak rhinovirus load 40-fold versus placebo in adults with asthma. The company reported no P values or confidence intervals for any outcome.
Why it matters
Rhinovirus infections are a common trigger of asthma exacerbations, so an agent that lowers viral load in the airway could address a clinically important driver of symptoms. The results are early and small, and the company has not yet shown the effect is statistically robust.
The figures come from a randomized, placebo-controlled challenge trial of 50 adults with symptomatic asthma, with peak lower respiratory symptom score 14% lower and the proportion developing a cold 37% lower with ETH47 versus placebo. Ethris did not disclose statistical significance for these comparisons, so the strength of the evidence remains unresolved.
The players
Ethris
Ethris is a company developing messenger RNA therapeutics delivered directly to the airway, and ETH47 is its lead investigational nasal candidate.
The details
Participants received a single nasal dose of ETH47, an investigational messenger RNA therapy encoding interferon lambda, or placebo one day before challenge with rhinovirus A16. No severe or serious adverse events were reported after the single dose, and challenge-related respiratory adverse events were 73% lower with ETH47.
Timeline
November 5, 2026: Ethris announced topline phase 2a ETH47 data.
Health Landscape
Interferon lambda acts mainly on epithelial surfaces such as the airway, which is why it has drawn interest as a mucosal antiviral strategy. ETH47 applies that biology through messenger RNA delivered to the nose, a route that remains at an early stage of clinical testing for asthma.
ETH47 remains investigational and is not available to patients, so people with asthma should continue their current treatment plans. Any future nasal therapy would need to be evaluated in larger trials before it could affect how rhinovirus-related asthma flares are managed.
The takeaway
Early challenge data suggest a nasal mRNA approach may dampen rhinovirus-driven symptoms in asthma, but without reported statistical significance the signal should be treated as preliminary. Larger, longer-term studies will be needed before clinicians can weigh it against existing asthma care.
What happens next
Ethris plans a multiple-ascending-dose phase 1 study in patients with asthma and COPD, a phase 2a rhinovirus challenge study in COPD, and phase 2b field studies, though no dates were given for these steps.
Further reading
Explore more on Asthma research and treatment developments.
More information
Read the Ethris topline phase 2a ETH47 data release for the company's full results.
Source note: This article includes information reported by Hcplive.
